Impact funds help fight dementia and antibiotic resistance
Marc Gitzinger started his “adventure” in antibiotics 12 years ago, co-founding Swiss start-up BioVersys to tackle deadly and drug-resistant pathogens, such as strains of tuberculosis. He has watched as even promising peer companies collapsed, and had to slow his own development programmes for fear of running out of money.
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!